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Background: The metabolic activation of clopidogrel is a two-step process. It has been suggested 
that paraoxonase-1 (PON1) is a rate-limiting enzyme in the conversion of 2-  oxo-clopidogrel to 
an active thiol metabolite. Conflicting results have been reported in regard to (1) the association 
of a common polymorphism of PON1 (Q192R) with reduced rates of   coronary stent thrombosis 
in patients taking clopidogrel and (2) its effects on platelet inhibition in patient populations of 
European descent. 
Methods: Blood samples from 151 subjects of mixed racial background with established 
coronary artery disease and who received clopidogrel were analyzed. Platelet aggregation was 
determined with light transmittance aggregometry and VerifyNow® P2Y12 assay. Genotyping 
for cytochrome P450 2C19 (CYP2C19)*2 and *3 and PON1 (Q192R) polymorphisms was 
performed.
Results: Carriers of CYP2C19*2 alleles exhibited lower levels of platelet inhibition and 
higher on-treatment platelet aggregation than noncarriers. There was no significant difference 
in platelet aggregation among PON1 Q192R genotypes. Homozygous carriers of the wild-type 
variant of PON1 (QQ192) had similar on-treatment platelet reactivity to carriers of increased-
function variant alleles during maintenance clopidogrel dosing, as well as after administration 
of a clopidogrel 600 mg loading dose.
Conclusion: CYP2C19*2 allele is associated with impaired platelet inhibition by clopidogrel 
and high on-treatment platelet aggregation. PON1 (Q192R) polymorphism does not appear to 
be a significant determinant of clopidogrel response.
Keywords: PON1, platelet, aggregation, cytochrome P450 enzymes
Introduction
Interindividual variations of ex vivo platelet aggregation during clopidogrel therapy 
have been correlated to reduced exposure of active clopidogrel thiol metabolite 
and differences in P2Y12 receptor occupancy.1 High on-treatment platelet reactiv-
ity during therapy with clopidogrel and low platelet inhibition are associated with 
risk of ischemic events after coronary stenting – in particular, stent thrombosis.1–5 
As compared with extensive metabolizers, carriers of cytochrome P450 2C19 
(CYP2C19) nonfunctional alleles have been shown to have reduced platelet inhibition 
by clopidogrel and are at increased risk of adverse events and stent thrombosis after 
coronary.5–9 Recent advances in the understanding of clopidogrel metabolism sug-
gest that the inactive prodrug undergoes two steps of bioactivation. First, clopidogrel 
undergoes   oxidation to 2-oxo-clopidogrel by hepatic CYP450 enzymes (1A2, 2B6, 
2C9, 2C19, and 3A4/5 isoenzymes). Then, in the second step of the biotransformation, 
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thiol metabolite is generated.10 A recent study employing 
sophisticated metabolomic methods suggested a hydrolytic 
process   involving paraoxonase-1 (PON1) as the rate-limiting 
enzyme.10 A   common polymorphism of PON1 (Q192R) is 
associated with reduced paraoxonase activity in carriers of the 
QQ (AA) haplotype. In two cohorts of patients with coronary 
stenting, and using a case study design, the investigators 
found the PON1 (QQ192) genotype was associated with 
increased risk of stent thrombosis.10 A group of patients with 
a history of prior stent thrombosis but who were not receiv-
ing current therapy with clopidogrel were administered a 
clopidogrel 600 mg loading dose. Within this group, reduced 
plasma activity of PON1 and PON1 (QQ192) genotype were 
associated with reduced active thiol metabolite exposure and 
reduced platelet inhibition by clopidogrel.10
Only one genome-wide association study (GWAS) has 
been performed examining the association of common genetic 
polymorphisms on platelet inhibition.11 This GWAS exam-
ined platelet aggregation data from 429 generally healthy 
white subjects of Amish descent after administration of a 
clopidogrel 300 mg loading dose, followed by maintenance 
clopidogrel dosing of 75 mg daily for 6 days. Platelet aggre-
gation was assessed before administration of clopidogrel and 
again after 6 days of maintenance dosing. The results from 
the GWAS only found single nucleotide polymorphisms 
(SNPs) on chromosome 10q24 in linkage equilibrium with 
the CYP2C19*2 loss-of-function variant to be significantly 
associated with clopidogrel platelet inhibition.11 The GWAS 
did not find evidence of a significant association of SNPs 
located on or near the PON1 gene on chromosome 7 with 
variation in platelet inhibition by clopidogrel.11
The aim of the current study was to assess the impact of 
PON1 (Q192R) and CYP2C19*2 polymorphisms on clopi-
dogrel platelet inhibition, as measured by light transmittance 
aggregometry and VerifyNow® (VN) P2Y12 assay, in a North 
American study population of mixed racial background.
Methods
Patients
The Indiana University School of Medicine’s Institutional 
Review Board for Research approved the study protocols. 
Informed consent was obtained from all subjects. Subjects 
were eligible to be enrolled if they had established coronary 
disease and were on dual antiplatelet therapy with clopidogrel 
and aspirin 81–325 mg daily for secondary prevention. Sub-
jects were included in this study either if they had been taking 
clopidogrel 75 mg for at least 14 days prior to enrollment or if 
they had received a clopidogrel 600 mg loading dose during 
a percutaneous coronary intervention (PCI). Subjects were 
excluded if they had a history of drug or alcohol abuse, bleed-
ing disorder, myelodysplastic or myeloproliferative disorders, 
chronic liver disease, or current warfarin use. Subjects were 
also excluded if they were pregnant, if the platelet count was 
less than 150,000/mm3, and if there was planned glycoprotein 
IIb/IIIa antagonist use during PCI. See Table 1 for baseline 
characteristics of the study subjects.
Blood samples
After 14 days of taking clopidogrel 75 mg daily, peripheral 
venous blood samples were obtained from subjects prior to the 
next dose of clopidogrel and aspirin to determine on-treatment 
platelet aggregation. For patients who received clopidogrel 
600 mg at the time of a PCI, a baseline blood sample was 
obtained from the arterial access sheath prior to administration 
of the clopidogrel loading dose and administration of heparin 
or bivalirudin. Peripheral venous blood samples were drawn 
at 4 and 16–24 hours after administration of the clopidogrel 
loading dose. For subjects who received a clopidogrel 600 mg 
loading dose, the 16- to 24-hour sample was used to determine 
the final on-treatment platelet aggregation used for the primary 
analysis of platelet aggregation among genotypes. All blood 
samples were directly transferred into vacutainer tubes contain-
ing 3.2% sodium citrate and were analyzed within 2 hours.
Platelet aggregation studies
Ex vivo platelet function was assessed by light transmit-
tance aggregometry (LTA) at 37°C with an Optical Lumi-
Aggregometer (Model 700 with AGGRO/LINK 8 software; 
Chrono-Log Corporation, Havertown, PA). Platelet-rich and 
platelet-poor plasma were obtained by differential centrifu-
gation, as previously described.12,13 Platelet aggregation in 
platelet-rich plasma was induced with adenosine diphosphate 
(ADP) at 5, 10, and 20 µmol/L.
A VN-P2Y12 point-of-care assay (Accumetrics, Inc, San 
Diego, CA) was used to assess platelet inhibition in whole 
blood in subjects during maintenance clopidogrel dosing, as 
previously described.14
genotyping
Genomic DNA was isolated from whole blood with the aid of 
the QIAamp® DNA Blood Midi Kit (Qiagen, Germantown, 
MD). Subjects were genotyped for CYP2C19*2 (681G.A; 
rs4244285), CYP2C19*3 (636G.A; rs4986893), and PON1 
(Q192R; 575 A.G; rs662) SNPs using a Bio-Rad Laboratories 
real-time iCycler thermal cycler (Bio-Rad Laboratories, Inc, 
  Hercules, CA). Sequence-specific primers were used to amplify 
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the alleles of interest, along with two allele-specific TaqMan® 
probes (Applied Biosystems, Foster City, CA). Allelic discrimi-
nation software (Optical System, v 3.1; Bio-Rad Laboratories) 
was used to determine individual genotypes.
Statistical analysis
Statistical significance was defined as P , 0.05. All statisti-
cal tests were two-sided, and values are represented as the 
mean plus or minus the standard deviation, unless otherwise 
specified. Categorical variables were compared using the 
chi-square test. The Kolmogorov–Smirnov test was used to 
assess the normal distribution of continuous data. Unpaired 
two-sided Student’s t-test was used to compare normally 
distributed continuous data between two groups and for 
genotype group comparisons using one-way analysis of 
variance. Non-normally distributed continuous data were 
compared across two groups with the two-sided unpaired 
Wilcoxon test and genotype group comparisons with the 
Kruskal–Wallis test. Genotypes for CYP2C19 and PON1 
were identified and included in univariate and multivariate 
linear regression, along with clinical variables that are known 
to affect platelet reactivity and response to clopidogrel and 
variables with P , 0.1 in univariate analysis (Table 2).
Results
Baseline characteristics of the study subjects are described 
according to CYP2C19*2 and PON1 Q192R genotypes in 
Table 1. Overall clinical variables were well balanced among 
genotype groups. A total of 96 subjects on maintenance 
clopidogrel therapy for over 14 days and 55 subjects who 
received a clopidogrel 600 mg loading dose at the time of 
PCI were enrolled. The prevalence of African-Americans 
was significantly different across PON1 Q192R genotypes, 
with a higher prevalence of African-Americans in carriers of 
PON1 QQ192 (Table 1). These findings are consistent with 
the increased prevalence of QQ192 genotypes previously 
described in the African population as compared with popula-
tions of European descent.15
Among the 151 patients included in this study, 
63 (42%) were carriers of the QQ192 genotype, 67 (44%) 
were heterozygous allele carriers (QR192), and 21 patients 
(14%) were homozygous RR192 genotype carriers. For the 
CYP2C19*2 allele, 107 (71%) were wild-type homozygous 
for the *2 allelic variant (*1/*1), 39 (26%) were heterozy-
gous *2 allele carriers (*1/*2), and five patients (3%) were 
homozygous *2 allele carriers (*2/*2). For both genotype 
distributions, no significant deviations from the Hardy–
Weinberg equilibrium were observed (P = 0.64 for PON1 
Q192R; P = 0.54 for CYP2C19*2 genotypes).
There were no CYP2C19*3 alleles detected in the study 
population, which is consistent with the very rare frequency 
(,1%) of this loss-of-function allele in Caucasians and African-
Americans. Platelet aggregation induced by ADP demonstrated 
wide interindividual variability during therapy with clopidogrel, 
as previously documented (Table 2,   Figures 1–4).1–5
PON1 QQ192 was not associated with increased platelet 
aggregation induced by ADP at various concentrations during 
clopidogrel therapy before and after adjustment for 2C19*2, 
diabetes mellitus, obesity, smoking, and proton pump inhibi-
tor therapy (Table 2). PON1 QQ192 was also not associated 
with increased VN-P2Y12 reactivity; in fact, there was a trend 
towards lower platelet reactivity in PON1 QQ192 individuals. 
No significant difference in the percentage of platelet inhibi-
tion measured by VN was documented among individuals 
of varying PON1 genotype (Table 2, Figure 2). Carriers of 
2C19*2 alleles had higher platelet aggregation and higher 
VN-P2Y12 reactivity with significantly lower VN platelet 
inhibition than noncarriers (Table 2, Figure 1).
Among the subgroup of patients who received a clopi-
dogrel 600 mg loading dose prior to undergoing PCI, 
Table 2 Platelet aggregation
LTA 5 μmol/L  
ADP (%)
LTA 10 μmol/L  
ADP (%)
LTA 20 μmol/L  
ADP (%)
VN-P2Y12  
result (PRU)
VN-P2Y12  
inhibition (%)
PON1 QQ192 (AA) (n = 63) 31.1 ± 12.2 37.8 ± 13.7 45.2 ± 10.8 192.9 ± 70 23.8 ± 20
PON1 QR192 (Ag) (n = 67)# 30.8 ± 15.7 37.7 ± 16 45.3 ± 13.6 205.9 ± 88 27.4 ± 27
PON1 RR192 (gg) (n = 21)# 32 ± 12.8 43.6 ± 10.9 48.6 ± 11.7 239.1 ± 53 12.6 ± 17
P-value (univariate) 0.7 0.74 0.96 0.167 0.913
P-value (multivariate) 0.81 0.89 0.87 0.081 0.638
2C19*2 Carriers (n = 44)# 37.9 ± 12 45.0 ± 13.1 51.3 ± 11 234.6 ± 67 12.9 ± 14
2C19*2 Noncarriers (n = 107)# 29.9 ± 11.2 36.2 ± 14.3 43.6 ± 12 195.0 ± 78 27.7 ± 25
P-value (univariate) 0.037 0.034 0.034 0.027 0.013
P-value (multivariate) 0.04 0.036 0.034 0.014 0.012
Note: #Values represent the mean plus or minus the standard deviation.
Abbreviations: ADP, adenosine diphosphate; lTA, light transmittance aggregometry; PON1, paraoxonase-1; PRU, platelet reactivity units; VN, VerifyNow®.
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platelet aggregation measured before and after administra-
tion of clopidogrel was not significantly different between 
subjects of PON1 QQ192 and QR192/RR192 genotypes 
(Figure 3). There was no significant difference in platelet 
inhibition among homozygous carriers of reduced-function 
PON1 (QQ192) and QR192 and RR192 genotypes at 4 and 
16–24 hours after administration of a clopidogrel 600 mg 
loading dose (Figure 3). In the same subgroup of patients who 
had received a clopidogrel 600 mg loading dose and who had 
a baseline platelet aggregation measurement, 2C19*2 carri-
ers status was associated with significantly lower percentage 
of platelet inhibition measured by ADP 10 µmol/L, without 
reaching statistical significance for other concentrations of 
ADP (Figure 4).
In the univariate linear regression analysis, only 2C19*2 
carrier status (ADP 10 µmol/L; P = 0.034), current smoking 
(ADP 10 µmol/L; P = 0.025), and weight (ADP 10 µmol/L; 
P = 0.018) were significantly associated with ADP-induced 
platelet aggregation. PON1 Q192R homozygous reduced-
function genotype (QQ192) (ADP 10 µmol/L; P = 0.7), 
diabetes (ADP 10 µmol/L; P = 0.22), and proton pump inhibi-
tor use (ADP 10 µmol/L; P = 0.65) were not significantly 
associated with ADP-induced platelet aggregation (Table 2). 
Covariates with P , 0.1 were included in a multivariate 
regression analysis, as well as variables such as diabetes 
and proton pump inhibitor use that have previously been 
established as affecting clopidogrel platelet inhibition.
In a multivariate linear regression analysis that included 
diabetes, smoking, obesity, and proton pump inhibitor use 
as variables in addition to PON1 Q192R and CYP2C19*2 
genotypes, CYP2C19*2 carrier status (ADP 10 µmol/L; 
P = 0.036), but not PON1 Q192R (ADP 10 µmol/L; P = 0.89), 
were associated with significant differences in ADP-induced 
platelet aggregation (Table 2).
Discussion
Clopidogrel bioactivation involves several enzymatic steps 
that have been delineated recently. In essence, clopidogrel is 
transformed into 2-oxo-clopidogrel by CYP450 enzymes and, 
in a second step, into the active thiol   metabolite.10 A recent 
metabolomic study suggested that PON1, a serum esterase, 
may represent the rate-limiting enzyme by hydrolysis of 
2-oxo-clopidogrel into thiol clopidogrel. Common SNPs of 
PON1 have been suggested to affect enzymatic activity of the 
enzyme. In Bouman et al’s10 study, PON1 activity was 
significantly reduced in subjects homozygous for the wild-
type allele (PON1 QQ192) compared with carriers of the 
mutant allele. In addition, in a group of patients with stent 
thrombosis and matched controls without stent thrombosis, 
PON1 QQ192 was associated with decreased platelet 
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Figure 1 Platelet aggregation represented as box plots and grouped according to cytochrome P450 2C19*2 genotype (*1/*1 [n = 107] vs *1/*2 [n = 39] vs *2/*2 [n = 5]). 
(A) Maximal platelet aggregation induced by adenosine diphosphate (ADP) 5 µmol/l (light transmittance aggregometry [lTA]); (B) maximal platelet aggregation induced 
by ADP 10 µmol/l (lTA); (C) maximal platelet aggregation induced by ADP 20 µmol/l (lTA); (D) VerifyNow® (VN) P2Y12 reactivity; (E) platelet inhibition measured by 
VN-P2Y12 assay.
Abbreviation: PRU, platelet reactivity units.
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  inhibition by clopidogrel and decreased plasma exposure to 
active thiol metabolite after a clopidogrel 600 mg loading 
dose. Also, PON1 QQ192 genotype was associated with 
an odds ratio of 3.3 for the occurrence of stent thrombosis 
as compared with QR192 or RR192 genotypes.10 The only 
GWAS on clopidogrel response had previously not found an 
association with SNPs located on or near the PON1 gene, but 
the platelet assays in that study were performed after 7 days of 
therapy with clopidogrel.11 The patients included in the GWAS 
were generally healthy white subjects, who had received a 
clopidogrel 300 mg loading dose followed by 75 mg daily for 
6 days prior to analysis of platelet aggregation.11
Similar to findings from other investigators since the pub-
lication of the study by Bouman et al,10 the current study could 
not document an association of PON1 (Q192R) genotype 
with platelet inhibition by clopidogrel in patients of mixed 
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Figure 3 Panels A and B represent data from patients not previously exposed to clopidogrel (n = 42) who received a clopidogrel 600 mg loading dose prior to coronary 
intervention and data are grouped according to PON1 genotype (QQ192 vs QR/RR192). (A) light transmittance aggregometry before and at 4 and 16–24 hours after 
a 600 mg loading dose of clopidogrel; (B) platelet inhibition (percent change from baseline measurement) at 4 and 16–24 hours after a clopidogrel 600 mg loading dose.
Note: Values represent the mean plus or minus the standard error of the mean.
Abbreviation: ADP, adenosine diphosphate.
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Figure 2 Platelet aggregation represented as box plots and grouped according to paraoxonase-1 (PON1) Q192R genotype (RR192 [n = 21] vs QR192 [n = 67] vs QQ192 [n = 63]). 
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submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
18
Kreutz et alClinical Pharmacology: Advances and Applications 2012:4
racial background with established coronary artery disease 
during treatment with clopidogrel.16–21 Neither platelet inhibi-
tion measured by VN-P2Y12 assay nor on-treatment platelet 
aggregation using various doses of ADP showed significant 
differences among genotypes of PON1 Q192R. Among the 
group of patients who received a clopidogrel 600 mg load-
ing dose immediately before PCI, platelet studies performed 
before and after administration of 600 mg of clopidogrel 
showed no significant differences in platelet aggregation 
among genotypes of PON1 Q192R (Figure 3).
The results of the current study are consistent with find-
ings of Shuldiner et al,11 who did not demonstrate an asso-
ciation of SNPs in or near the PON1 gene with clopidogrel 
nonresponse during clopidogrel maintenance dosing, and 
they confirm the association of 2C19*2 polymorphism with 
reduced platelet inhibition by clopidogrel.22,23
In the current study, CYP2C19*2 carrier status was 
associated with reduced platelet inhibition, as measured by 
VN-P2Y12 assay and LTA 10 µmol/L, and increased on-
treatment platelet reactivity, as measured by both LTA and 
VN-P2Y12 assay (Table 2, Figures 1 and 4).
CYP2C19*2 polymorphism has been demonstrated 
to be a strong determinant of reduced active clopidogrel 
metabolite formation, increased on-treatment ADP-induced 
platelet reactivity, and clinical ischemic events after coronary 
stenting.5–9,11,22,23 In a meta-analysis investigating the effect of 
reduced-function 2C19 alleles on recurrent ischemic events 
in patients receiving clopidogrel after coronary stenting, 
the presence of one reduced-function allele was associated 
with a hazard ratio of 2.67 and the presence of two reduced-
function alleles was associated with a hazard ratio of 3.97 for 
the occurrence of stent thrombosis. These findings support 
the clinical importance of the reduced-function CYP2C19*2 
polymorphism and clopidogrel nonresponse after coronary 
stenting.9
Although not supported by the findings of this study, that 
PON1 Q192R polymorphisms could affect the generation 
of active thiol metabolite with administration of 600 mg or 
greater loading doses (as suggested by the findings of Bouman 
et al)10 and that it could be associated with small differences in 
platelet inhibition cannot be excluded.10 However, in contrast 
to Bouman et al’s10 study, several investigators were unable to 
confirm the association between PON1 Q192R genotypes and 
stent thrombosis in other independent large cohorts of patients 
undergoing PCI who were treated with clopidogrel.16–21
Limitations of the study include a relatively small sample 
size and a lack of pharmacokinetic analysis to detect differ-
ences in active metabolite concentrations. In addition, the 
authors did not directly measure PON1 activity in plasma. 
Although considered the gold standard for measuring plate-
let aggregation and clopidogrel platelet inhibition, LTA is 
subject to operator variability, and on-treatment platelet 
aggregation may not be a direct reflection of P2Y12 receptor 
inhibition by active clopidogrel metabolites.
Conclusion
This study confirms the previously reported impact of 
reduced-function CYP2C19*2 polymorphism on platelet 
inhibition by clopidogrel. Polymorphisms of PON1 Q192R 
appear not to be predictive of clopidogrel response when 
measured by LTA and VN-P2Y12 assay in patients with 
coronary artery disease.
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Figure 4 Panels A and B represent data from patients not previously exposed to clopidogrel (n = 42) who received a clopidogrel 600 mg loading dose prior to coronary 
intervention and data are grouped according to 2C19*2 genotype (*1/*1 vs *2 carriers). (A) light transmittance aggregometry before and at 4 and 16–24 hours after a 600 mg 
loading dose of clopidogrel; (B) platelet inhibition (percent change from baseline measurement) at 4 and 16–24 hours after a clopidogrel 600 mg loading dose.
Note: Values represent the mean plus or minus the standard error of the mean.
Abbreviation: ADP, adenosine diphosphate.
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